Sino Biopharmaceutical Limited operates as a leading investment holding entity and a research and development-focused pharmaceutical conglomerate, primarily active within the People's Republic of China. Its business activities are organized into three primary divisions: Modernised Chinese Medicines and Chemical Medicines, Investment initiatives, and other miscellaneous operations. The company offers a comprehensive range of pharmaceutical products spanning various therapeutic areas. This portfolio includes oncology medications like Qingkeshu, Anxian, Yinishu, Genike, Anyue capsules, and Leweixin injections; cardio-cerebral vascular drugs such as Kaina and Anrixin tablets; and treatments for hepatitis, including Tianqingganmei injections and Tianqingganping enteric capsules. It also produces orthopedic medicines like Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medications; parenteral nutritious solutions such as Xinhaineng and Fenghaina injections; and other pharmaceuticals, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. Furthermore, its advanced drug offerings feature specific products like Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond its core pharmaceutical manufacturing, Sino Biopharmaceutical engages in a diverse set of related healthcare and commercial ventures. These encompass managing properties; the retail and distribution of pharmaceutical goods; providing optometry services and selling ophthalmic products; operating hospitals; and offering medical management, health information consultancy, and bio-tech transfer and advisory services. The company also manufactures and markets health food, performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical eyewear, and is involved in the research, development, and sale of medical devices and active pharmaceutical ingredients. The company was established in 2000 and has its corporate headquarters situated in Wan Chai, Hong Kong.
What is Sino Biopharmaceutical stock price today?▼
The current price of SBMFF is $0.70 USD — it has decreased by -5.01% in the past 24 hours. Watch Sino Biopharmaceutical stock price performance more closely on the chart.
What is Sino Biopharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Sino Biopharmaceutical stocks are traded under the ticker SBMFF.
Is Sino Biopharmaceutical stock price growing?▼
SBMFF stock has risen by +7.7% compared to the previous week, the month change is a +14.92% rise, over the last year Sino Biopharmaceutical has showed a -43.47% decrease.
What is Sino Biopharmaceutical market cap?▼
Today Sino Biopharmaceutical has the market capitalization of 13.15B
When is the next Sino Biopharmaceutical earnings date?▼
Sino Biopharmaceutical is going to release the next earnings report on April 01, 2027.
What were Sino Biopharmaceutical earnings last quarter?▼
SBMFF earnings for the last quarter are 0.03 USD per share, whereas the estimation was 0.02 USD resulting in a +58.58% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sino Biopharmaceutical revenue for the last year?▼
Sino Biopharmaceutical revenue for the last year amounts to 4.49B USD.
What is Sino Biopharmaceutical net income for the last year?▼
SBMFF net income for the last year is 323.63M USD.
Does Sino Biopharmaceutical pay dividends?▼
Yes, SBMFF dividends are paid semi-annual. The last dividend per share was 0.01 USD. As of today, Dividend Yield (FWD)% is 2.55%.
How many employees does Sino Biopharmaceutical have?▼
As of September 11, 2026, the company has 21,435 employees.
In which sector is Sino Biopharmaceutical located?▼
Sino Biopharmaceutical operates in the Health & Wellness sector.
When did Sino Biopharmaceutical complete a stock split?▼
The last stock split for Sino Biopharmaceutical was on August 14, 2020 with a ratio of 1.5:1.
Where is Sino Biopharmaceutical headquartered?▼
Sino Biopharmaceutical is headquartered in Hong Kong, Cayman Islands.